Bacterial Antigens Market Share, Size, Trends, Industry Analysis Report, By Antigen Type (Clostridium Difficile Toxoid A, Clostridium Difficile B, Chlamydia Trachomatis, Native Lipoteichoic Acid, Trichomonas Vaginalis, and Others); By Diagnostic Technique

Bacterial Antigens Market Share, Size, Trends, Industry Analysis Report, By Antigen Type (Clostridium Difficile Toxoid A, Clostridium Difficile B, Chlamydia Trachomatis, Native Lipoteichoic Acid, Trichomonas Vaginalis, and Others); By Diagnostic Techniques; By End User; By Region; Segment Forecast, 2023 – 2032

The global bacterial antigens market size is expected to reach USD 20.09 million by 2032, according to a new study by Polaris Market Research. The report “Bacterial Antigens Market Share, Size, Trends, Industry Analysis Report, By Antigen Type (Clostridium Difficile Toxoid A, Clostridium Difficile B, Chlamydia Trachomatis, Native Lipoteichoic Acid, Trichomonas Vaginalis, and Others); By Diagnostic Techniques; By End User; By Region; Segment Forecast, 2023 - 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The constant increase in the burden of infectious diseases globally and widespread adoption and need for effective diagnostic and therapeutic solutions, along with the growing people awareness towards the importance of vaccinations and the rising number of new vaccine developments that require bacterial antigens for their formulations, are major prominent factors boosting the market demand and growth.

Furthermore, ongoing improvements in biomanufacturing processes could lead to more efficient and cost-effective production of bacterial antigens while enhancing the accessibility of vaccines and diagnostic tools, particularly in developing countries and growing investments in research development activities focused on innovating antigens features and capabilities, will likely to propel the product demand in the near future.

For instance, in May 2023, Evaxion unveiled a new adjuvant technology that boosts the overall immune response of viral, bacterial, and cancer vaccines. This technology also induces neutralizing antibodies and T-cell responses against both viral and bacterial antigens.

With the continuous expansion in healthcare expenditure, especially in emerging economies due to various invisible demographic and epidemiologic trends, that are significantly supported by several policy factors like liberalized foreign investment norms, medical devices parks and regulations, and incentives for setting up dedicated bulk-drug, there will be lucrative opportunities for bacterial antigens to be adopted and used in healthcare settings globally.

Besides this, there has been increasing demand for rapid and accurate point-of-care diagnostic tests, particularly in resource-limited settings, and greater prevalence for developing bacterial antigen-based tests that are easy to deploy and use in various healthcare settings, including hospitals and diagnostic laboratories, and have paved the way for significant revenue opportunities for companies operating in the market.

Bacterial Antigens Market Report Highlights

Clostridium difficile toxoid A segment accounted for largest share, mainly due to rising incidences of bacterial infections into the healthcare settings

Immunoassay segment held the maximum share, on account of increasing advancements in immunoassay technologies globally

Academic & research institutes segment will grow at fastest pace, because of the rising need for bacterial antigens in research institutes to study different aspects of antigens

North America region dominated the global market, owing to surge in the number of favorable government initiatives and higher awareness among people

The key market players include Ross Southern Laboratories, Thermo Fisher Scientific, The Native Antigen Company, Enzo Life Sciences, and Creative Diagnostics

Polaris Market Research has segmented the bacterial antigens market report based on antigen type, diagnostic techniques, end user, and region:

Bacterial Antigens, Antigen Type Outlook (Revenue - USD Million, 2019 - 2032)

Clostridium Difficile Toxoid A

Clostridium Difficile B

Chlamydia Trachomatis

Native Lipoteichoic Acid

Trichomonas Vaginalis

Others

Bacterial Antigens, Diagnostic Techniques Outlook (Revenue - USD Million, 2019 - 2032)

ELISA

Immunoassay

SDS-PAGE

Hemagglutination

Agglutination Test

Others

Bacterial Antigens, End User Outlook (Revenue - USD Million, 2019 - 2032)

Diagnostic Laboratories and Centers

Academic Research Institutes

Hospital

Bacterial Antigens, Regional Outlook (Revenue - USD Million, 2019 - 2032)

North America

U.S.

Canada

Europe

Germany

UK

France

Italy

Spain

Russia

Netherlands

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Latin America

Argentina

Brazil

Mexico

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa